In the absence of head-to-head trials of first-line treatments for chronic lymphocytic leukemia (CLL), a newly published matching-adjusted indirect comparison (MAIC) provides the clearest evidence to date on how continuous zanubrutinib (Brukinsa; BeiGene) and fixed-duration venetoclax (Venclexta; AbbVie and Genentech) plus ibrutinib (Imbruvica; Pharmacyclics) (V+I) stack up against each other.
While progression-free survival outcomes are broadly similar between zanubrutinib and venetoclax, the btki demonstrates a notably more favorable safety profile. | Image credit: laszlo-stock.adobe.com
Zanubrutinib Shows Favorable Safety Profile Compared to Ibrutinib in CLL, Study Finds
Recent research suggests that zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, offers a notably more favorable safety profile compared to ibrutinib, another BTK inhibitor commonly used in the treatment of chronic lymphocytic leukemia (CLL). while progression-free survival (PFS) outcomes appear broadly similar between the two drugs, the study highlights significant differences in adverse event rates.
The research team utilized patient-level data from the SEQUOIA trial, encompassing 479 treatment-naïve patients with CLL without del(17p) and 111 with del(17p), all treated with zanubrutinib.This data was meticulously matched to aggregated baseline characteristics from two major ibrutinib-plus-venetoclax (V+I) studies: GLOW, a phase 3 trial focusing on older patients with comorbidities, and CAPTIVATE, a phase 2 trial involving younger, fitter patients. V+I is currently approved in Europe and Canada.
The findings indicate that despite comparable efficacy, zanubrutinib is associated with a lower incidence of certain adverse events, potentially leading to improved patient tolerance and quality of life. This research provides valuable insights for clinicians when selecting the most appropriate BTK inhibitor for individual patients with CLL.
Zanubrutinib Shows Promising Real-World Outcomes in CLL, Indirect Comparison Suggests
An indirect comparison suggests zanubrutinib may offer a favorable efficacy and safety profile compared to fixed-duration venetoclax plus ibrutinib for treatment-naïve chronic lymphocytic leukemia (CLL). The study, published in the British Journal of Haematology, utilized a matching-adjusted indirect comparison (MAIC) methodology to analyze data from the CAPTIVATE trial (zanubrutinib) and clinical trial data supporting the approval of venetoclax/ibrutinib.
Researchers found that progression-free survival (PFS) favored zanubrutinib, although the difference was not statistically significant. A numerical separation in PFS beyond 3 years suggests a potential for long-term benefit, warranting further investigation. The analysis also highlighted a potential tolerability advantage for zanubrutinib, with consistent safety results and limited side effect reporting in the CAPTIVATE trial focused on rates above predefined thresholds.
Though, the authors caution that MAIC methodology has limitations and cannot fully replace direct randomized comparisons, particularly given population imbalances and small comparator-arm sample sizes. The study noted a lack of quality-of-life outcomes for comparison, but researchers anticipate a positive impact from zanubrutinib based on its safety profile – a factor that could influence treatment decisions for clinicians and patients.
References
- munir T, Mohseninejad L, Rakonczai P, et al. Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naïve chronic lymphocytic leukaemia. Br J Haem. Published online November 11, 2025, doi:10,1111/bjh,70241
- european Commission approves Imbruvica (ibrutinib) in a fixed-duration combination regimen for adult patients with previously untreated chronic lymphocytic leukaemia (CLL). News release. Johnson & Johnson. Published online August 4, 2022. Accessed November 20, 2025. https://www.jnj.com/media-center/press-releases/european-commission-approves-imbruvica-ibrutinib-in-a-fixed-duration-combination-regimen-for-adult-patients-with-previously-untreated-chronic
Keep reading